Semaglutide tracker

Semaglutide is a long-acting GLP-1 receptor agonist originally developed by Novo Nordisk. It works by binding to and activating the GLP-1 receptor, which slows gastric emptying, augments glucose-dependent insulin secretion, and suppresses glucagon release. The molecule is acylated with a C18 fatty-acid side chain that binds reversibly to albumin, extending its terminal half-life to approximately 165 hours and enabling once-weekly subcutaneous dosing. Clinically, it is used for glycaemic control in type 2 diabetes and for chronic weight management under the brand names Ozempic and Wegovy. Common rotation sites include the abdomen, thigh, and upper arm. Regular tracking of dose timing, injection site, and gastrointestinal side effects is recommended to manage tolerance and adherence.